GEROPHARM as a global biotech company develops and produces all kinds of insulins, GLP-1 molecules, bioregulatory peptides and orphan drugs. GEROPHARM holds the leading position at diabetes and weight-loss market in Russia.
GEROPHARM is presented all over the world. Its products are marketed in Venezuela, Cuba, Marocco, Yemen, Myanmar, Paraguay and CIS countries.

R-Pharm Group introduces comprehensive solutions for the healthcare system and focuses on research, development, manufacturing and commercialization of pharmaceuticals, laboratory equipment and medical devices.
R-Pharm's 11 state-of-the-art manufacturing sites are functioning in accordance with international quality standards. More than 5,000 employees work in the offices and production facilities of the group of companies.
Today, R-Pharm's research pipeline contains more than 100 knowledge-intensive products, which make a serious contribution to the fight against high burden diseases.
The group has signed agreements on strategic partnership, production localization and technology transfer with the world’s leading manufacturers of pharmaceuticals and medical equipment.
Following corporate social responsibility policies, R-Pharm organizes projects aiming to increase awareness about dangerous diseases and foster a new generation of professionals in the pharmaceutical industry.

PJSC "PROMOMED" is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market. The company’s structure includes its own unique world-class R&D center and a high-tech manufacturing facility — the "BIOKHIMIK" plant. Thanks to this, PROMOMED implements the full-cycle production concept "from idea to molecule, from molecule to patient". The company is developing a diversified portfolio of over 355 medicines in the top 10 segments of the pharmaceutical market, including those that have no analogues in Russia. Based on its own developments, PROMOMED produces drugs for the treatment of socially significant diseases: oncological, neurological, rheumatic, infectious diseases, diabetes mellitus, obesity, and others.
The company is an active participant in the system ensuring national drug security and import independence. In 2025, PROMOMED celebrates its 20th anniversary.

A multi-faceted learning, research and expert platform, the Eurasian Academy of Good Practices fosters the growth of the pharmaceutical industry. The Academy was established upon the initiative of the EAEU pharmaceutical inspectorates with the support of the Ministry of Industry and Trade of the Russian Federation. The Academy's Board of Trustees includes representatives of the EAEU regulatory authorities, Russian and international pharmaceutical associations, and leading pharma companies.
Our key goals:

• Ensuring strategic integration of pharmaceutical education in lifelong learning: college → university → continuing professional education
• Assisting regulatory authorities and drug circulation entities in GxP appraisal & consulting
• Helping Russia's pharmaceutical industry attain technological independence by fostering innovation
• Promoting the domestic pharmaceutical industry and its achievements

What we do:
TRAINING | RESEARCH & CONSULTING | APPRAISAL | OUTREACH ACTIVITIES

GxP News is an industry media outlet focused on the professional pharmaceutical community. It’s an international information platform for dialogue between the pharmaceutical industry and regulators, a venue for the exchange of experience and opinions. Our information resources include a website and a print magazine. We publish daily news, expert articles, columns, and interviews. We are a media partner
for all major industry events.